anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided is a medical information system for a hospital, which enables hospitals to provide counseling services to existing patients based on electronic medical records of existing patients and to actively attract new patient customers by discovering marketing targets, that is, potential medical service users, and is capable of construction at a low cost. A treatment terminal is used to input and display the medical records of the visiting patient, and a consultation terminal is used to input and display contents of the consultation provided by a CRM counselor to the patient and potential customers. The server includes an electronic medical record database and a consultation content database, and provides the medical record and/or consultation content to a plurality of clients including the treatment terminal and the consultation terminal. The display control program detects patient identification information from a data packet transmitted and received by the consultation terminal when the consultation contents are displayed on the first display window in the consultation terminal. The patient medical record related to the patient identification information is read from the electronic medical record database and displayed on the second display window. In addition, the display control program detects the patient identification information from the data packet transmitted and received by the treatment terminal when the medical record of the patient is displayed on the third display window in the treatment terminal. The consultation contents related to the patient identification information are read from the consultation contents database and displayed on the fourth display window.
Valacyclovir hydrochloride USP is the hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir.

Valacyclovir tablets, USP are for oral administration. Each tablet contains valacyclovir hydrochloride USP equivalent to 500 mg or 1 gram valacyclovir and the inactive ingredients carnauba wax, FD & C blue #2, hypromellose, magnesium stearate, polyethylene glycol 400, polysorbate 80, starch pregelatinized and titanium dioxide. 

The chemical name of valacyclovir hydrochloride USP is L-valine, 2-[(2-amino-1,6-dihydro-6­ oxo-9H-purin-9-yl)methoxy]ethyl ester, monohydrochloride. It has the following structural formula:

Valacyclovir hydrochloride USP is a white or almost white powder with the molecular formula C13H20N6O4•HCl and a molecular weight of 360.80. The maximum solubility in water at 25°C is 174 mg/mL. The pka’s for valacyclovir hydrochloride USP are 1.90, 7.47, and 9.43.
Type 2 diabetes mellitus (T2DM) is a non-communicable disease representing one of the most serious public health challenges of the 21st century. Its incidence continues to rise in both developed and developing countries, causing the death of 1.5 million people every year. The use of technology (e.g. Smartphone application - App) in the health field has progressively increased as it has been proved effective in helping some individuals manage their long-term diseases. Therefore, it has the potential to reduce health service utilization and its related costs. The objective of this study is to evaluate the impact of using a digital platform called "TreC Diabete" embedded into a novel organizational asset targeting poorly controlled T2DM individuals in the Autonomous Province of Trento (PAT), Italy.This trial was designed as a multi-center, open-label, randomised, superiority study with two parallel-groups and a 1:1 allocation ratio. Individuals regularly attending outpatients diabetes clinics, providing informed consent are randomised to be prescribed TreC Diabete platform or not as part of their personalised care plan. Healthcare staff members will remotely assess the data shared by the participants through the App by using a dedicated online medical dashboard. The primary end-point is the evaluation of the Hb1Ac level at 12-month post-randomisation. Data will be analysed on an intention-to-treat (ITT) basis.This trial is the first conducted in the PAT for the use of an App specifically designed for individuals with poorly controlled T2DM. If the effects of introducing this specific App within a new organizational asset are positive, the digital platform will represent a possible way for people diagnosed with T2DM to better manage their health in the future. Results will be disseminated through conferences and peer-reviewed journals once the study is completed.
Ertapenem has received FDA approval for the indication of acute pelvic infection, though there is no pharmacokinetic data to guide dosing of ertapenem in postpartum women. The physiologic changes of the postpartum period make it likely that this special population requires dosing modification to achieve desired therapeutic targets. The objective of this study is to obtain a detailed knowledge of the pharmacokinetics of ertapenem during the postpartum period that will result in improved guidelines on maternal dosing and neonatal exposure. This is a prospective, open-label, single center, pharmacokinetic study of ertapenem in women diagnosed with postpartum endometritis. Subjects will include up to 24 women receiving treatment for a diagnosis of postpartum endometritis with ertapenem in the Duke University Hospital Labor \& Delivery Unit. Each patient will participate in the study for approximately 7 days, though the total study duration is expected to be approximately 12 months. Descriptive statistics for the subjects will be calculated. The appropriate non-compartmental pharmacokinetic parameters will be computed, including AUC24, AUCss, Cmax, CL, Vss, t1/2. All subjects who receive one dose of study drug will be followed for safety, with planned internal review of safety data following the completion of 12 patients. Nursing infants of study subjects will also be followed for safety due to the potential for exposure to study drug through breastmilk.
The stress response to surgery is a result of tissue injury with local and systemic inflammation that contributes to the postoperative outcome. Anesthesia is known to effect perioperative stress response. Regional anesthesia modifies stress response through afferent blockage whereas general anesthesia affects the stress response via central modulation. High sensitive C-reactive protein and neutrophil to lymphocyte ratio are used for evaluation of inflammation. The degree of systemic inflammation has been determined by numerous pro- and anti-inflammatory cytokines.The cytokines control the release of C -reactive protein (CRP) which is an acute phase reactant produced by the liver. CRP is a widely used marker of inflammation and tissue damage. High sensitive C -reactive protein (hs-CRP), is a more sensitive assay for detection of inflammation measured by particle-enhanced immunonephelometry . A rapid increase in hs-CRP may indicate inflammation and tissue damage . Another well-known indicator of inflammation is neutrophil-to-lymphocyte ratio (NLR). NLR correlates strongly with elevated plasma levels of circulating proinflammatory cytokineS. The aim of this study was to document the value hs-CRP and NLR in perioperative stress response in two different anesthesia methods applied to term pregnant women undergoing elective ceserean section (C/S).
PURPOSE:To provide an external drug for skin, free from hormonic side effects, mild to the skin, and having excellent remedying effect to pimples, by compounding a specific antiandrogen with a kelatolytic agent, a gelling agent and/ or an alcohol. CONSTITUTION:The objective drug for external use can be prepared by compounding the compound of formula (the dotted line is single or double bond), its ester or ether with a kelatolytic agent (e.g. urea, resorcinol, etc.), a gelling agent (e.g. carboxyvinyl polymer, CMC, etc.) and/or an alcohol (e.g. ethanol, benzyl alcohol, etc.). The combination of the compound of formula with the kelatolytic agent improves the solubility of the compound of formula, mitigates the stimulation of the kelatolytic agent, and achieves the quick cure of pimple by the increased absorption. The amount of the compound of formula in the agent is 0.001-2W/V% and that of the kelatolytic agent is 0.001-15W/V%.
BACKGROUND: Atrial fibrillation (AF) and obesity coexist in approximately 37.6 million and 650 million people globally, respectively. The anatomical and physiological changes in individuals with obesity may influence the pharmacokinetic properties of drugs.
AIM: This review aimed to describe the evidence of the effect of obesity on the pharmacokinetics of antiarrhythmics in people with AF.
METHODS: Three databases were searched from inception to June 2023. Original studies that addressed the use of antiarrhythmics in adults with AF and concomitant obesity were included.
RESULTS: A total of 4549 de-duplicated articles were screened, and 114 articles underwent full-text review. Ten studies were included in this narrative synthesis: seven cohort studies, two pharmacokinetic studies, and a single case report. Samples ranged from 1 to 371 participants, predominately males (41%-85%), aged 59-75 years, with a body mass index (BMI) of 23-66 kg/m2. The two most frequently investigated antiarrhythmics were amiodarone and dofetilide. Other drugs investigated included diltiazem, flecainide, disopyramide, propafenone, dronedarone, sotalol, vernakalant, and ibutilide. Findings indicate that obesity may affect the pharmacokinetics of amiodarone and sodium channel blockers (e.g., flecainide, disopyramide, and propafenone). Factors such as drug lipophilicity may also influence the pharmacokinetics of the drug and the need for dose modification.
DISCUSSION: Antiarrhythmics are not uniformly affected by obesity. This observation is based on heterogeneous studies of participants with an average BMI and poorly controlled confounding factors such as multimorbidity, concomitant medications, varying routes of administration, and assessment of obesity. Controlled trials with stratification at the time of recruitment for obesity are necessary to determine the significance of these findings.
Solid organ transplant (SOT) recipients undergo life-long immunosuppression to prevent allograft rejection. However, this also puts patients at significant risk for opportunistic infection. The degree of immunosuppression varies for each individual and is likely influenced by a combination of clinical factors such as antirejection medication, comorbidities, patient age as well as the state of patient immune system. Thus far, there have been no standardized methods to quantify the degree of global immunosuppression. A new blood test (Quantiferon-Monitor) has been recently developed that might help predict the level of immune suppression. The purpose of this study is to determine whether this new test will help determine a person's level of immune suppression after organ transplant. This will be done by trying to relate the level of immunity with the development of infection or rejection. If the test for immunosuppression is helpful, it may help us to better take into account the differences in patients when designing therapy. Ultimately, it may help develop better ways for preventing infections and transplant rejections.
BACKGROUND: Researchers have studied the risk factors for epilepsy recurrence among patients who withdraw from antiseizure medication (ASM). These studies aimed to determine the optimal time for ASM withdrawal. EEG findings are one of the risk factors that has been studied. However, it remains unclear whether abnormal pretreatment EEG findings are a risk factor for recurrence after ASM withdrawal. We performed this meta-analysis to clarify this issue.
METHODS: We retrieved literature from the PubMed and Embase databases, and used the NewcastleOttawa Scale to evaluate the methodological quality of the included studies. RevMan 5.3 software was used to analyse the data.
RESULTS: In total,710 articles were retrieved from the databases. Ultimately, after screening, 11 articles involving 1686 patients with epilepsy were included. Compared with that for a normal EEG, the odds ratio (OR) for an abnormal EEG was 1.10 (P=0.50), with an I2 value of 32% (P=0.15). Subgroup analysis revealed that the children-to-adolescents subgroup had an OR of 1.21 (P=0.27), and the children-to-adults subgroup had an OR of 0.64 (P=0.14) for an abnormal EEG. A separate subgroup analysis revealed that the focal epilepsy subgroup had an OR of 1.30 (P=0.37), and the generalized epilepsy and focal epilepsy subgroup had an OR of 1.07 (P=0.67) for an abnormal EEG.
CONCLUSIONS: The risk of epilepsy recurrence is not related to pretreatment EEG findings, regardless of age or epilepsy classification. The associations of pre- and posttreatment EEG alterations with epilepsy recurrence are controversial. Due to the limitations of our article, further research is needed.
Since pyrazinamide is in fact a prodrug of pyrazinoic acid, other prodrugs of pyrazinoic acid, like esters, could have activity against  M. tuberculosis . These compounds should be resistant to the human plasma and liver enzymes, but must be readily hydrolyzed, by mycobacteria, at the site of action. Esters were proposed in the past as prodrugs of pyrazinoic acid. The main advantage of those compounds is that they are not activated by a specific enzyme (pirazinamidase) but by a large array of esterases preventing the onset of resistance by this mechanism. However, these compounds must reach the mycobacteria in the prodrug form otherwise they cannot penetrate the mycobacterial wall and since plasma has also esterases the compounds studied were rapidly hydrolysed. Amide prodrugs are resistant to plasma hydrolysis however the compounds cannot be activated efficiently by mycobacterial esterases and do not present activity. New branched lipophilic esters were synthesized in order to delay their hydrolysis through the human plasma and liver before reaching the target mycobacteria. Their pseudo-first order rate constants for the hydrolysis in human plasma were evaluated as well as their activity against  M. tuberculosis  H37Ra. Branches in the first alkyl carbon, adjacent to the ester function, unexpectedly increased the stability and maintained the activity. The good stability of these compounds along with their activity against  M. tuberculosis  were the main achievements of this invention.
Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram \[mg\]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
A 26-year-old Indian man who had arrived in Japan 24 days prior presented to our hospital with abdominal pain and a fever. A blood test revealed marked hepatic dysfunction, and imaging tests confirmed a diagnosis of acute hepatitis. The patient's liver function and coagulability deteriorated, and his general condition was poor. Given the possibility of fulminant hepatic failure, we initiated steroid pulse therapy. Following the initiation of steroid therapy, the patient's liver function and subjective symptoms rapidly improved. Testing revealed positive findings for IgA-hepatitis E virus, and a genetic analysis of hepatitis E identified genotype 1, which is not endemic to Japan, leading to a definitive diagnosis of imported hepatitis E infection from India. The successful response to steroid therapy highlights the potential benefit of this approach in managing severe cases of acute hepatitis E, a rare occurrence in Japan. This case underscores the importance of considering hepatitis E infection in individuals with a recent travel history to regions with high prevalence and the potential benefits of steroid therapy in managing severe cases of acute hepatitis E.
Rathke's cleft cyst (RCC) apoplexy is an uncommon lesion attributed to abnormal vascular supply to the fragile RCC epithelial wall. It is rare in children and very difficult to diagnose without pathologic confirmation. Here, we report an 8-year-old boy who presented with headache and visual deficit. MRI and CT showed a cystic mass in the sellar region. He underwent endoscopic endonasal surgery, and the cystic mass was resected completely via a trans-sphenoidal approach. The lesion was confirmed as RCC apoplexy by intraoperative observation and histopathological examination. Headache was completely relieved and the visual field deficit improved remarkably after the operation. The authors recommend surgical management for pediatric RCC apoplexy patients who present with severe neuro-ophthalmic signs or deterioration of consciousness, although there are at present no standardized management guidelines for pediatric RCC apoplexy.
The present invention relates to a Chinese medicine capsule for curing cardiac and cerebral vascular diseases and a production method thereof, which can effectively solve the problem of medicine treatment of cerebral vascular diseases. The present invention has the technical scheme that the Chinese medicine capsule of the present invention is made of angelica, ligustrazine, red peony root, walnut kernel, red sage root, dried leech, safflower, scorpion, gentian root, uncaria, gastrodia tuber wall-bracken spore powder, prepared rhubarb, arisaema with bile, rehmannia root, radix scrophulariae, mistletoe, antelope horn powder, grass-leaved sweetflag, milk vetch, ginseng, spatholobus stem and cyathula root. The present invention has the preparation method that the gastrodia tuber wall-bracken spore powder is ground into fine powder, and then, the rest drugs are divided into two equal parts, wherein one part is decocted to physic liquor by adding water, and the physic liquor is concentrated to paste liquid; crude drugs of the other part are pulverized to fine powder which is uniformly mixed with the wall-bracken powder and the paste liquid. Then, the crude drugs are dried until the water content is less than 3%, and are encapsulated after sterilization. The present invention has the advantages of good medicine curative effect, convenience for taking and simple production method. The present invention has creativity contribution for the existing traditional Chinese medicine, and has wide development and application foreground.
The invention relates to the biological technical field and aims at providing abalone HINT gene and protein in an abalone and an application of the same for preparing an anticarcinogenic drug. The protein coded by the abalone HINT gene has amino acid sequences shown in SEQ ID NO:2. The gene coding the protein has nucleotide sequences shown in SEQ ID NO:1. The invention also provides the application of the protein for preparing the anticarcinogenic drug. The invention obtains the gene nucleotide complete sequence of the abalone HINT, c and expresses the soluble HINT protein product through constructing procaryon expressing carriers. The protein has the function of promoting hepatoma cell to be apoptotic, can be used as the component for inducing the cell apoptosis and can be applied to the preparation of the anticarcinogenic drug.
This will be a randomized, cross-over, unblinded study with subjects randomized upon entry into the study to either begin using the Klue software for 6 weeks or to continue with their usual care for 6 weeks. Subjects are eligible for enrollment if they are using a continuous glucose monitor (CGM) and insulin pumps or an insulin pen with memory and CGM, are missing or late in giving at least 4 food boluses in the previous two weeks, and they have an iPhone. Missing or late meal boluses will be assessed through their pump/pen and sensor downloads. This is a pilot study. The investigators do not have preliminary data to do a true power calculation. The primary outcome will be the change in the number of missed meal boluses in the two weeks prior to each visit. Secondary outcome measures will be the number of missed meal boluses in each month of the study, change in HbA1c levels (measured every 6 weeks), accuracy of the Klue software in detecting meals (true positive and false positive rates), and a user satisfaction survey.
Participants will be identified by orthopedic surgeon. Once informed consent is obtained participants will subsequently be randomly assigned to the control or experimental block associated with their diagnosis. Patients will be randomly assigned within their diagnosis block through random number generation in Microsoft Excel. Participants randomly assigned to the control group will receive the current \& typical educational information provided by their orthopedic surgeon. Participants randomly assigned to the experimental group will receive an additional occupational therapy (OT) focused pre-operation education consultation provided by a third year occupational therapy student under the supervision of an orthopedic surgeon \& Occupational Therapist \& Certified Hand Therapist. The additional OT pre-operative consult will be included during participants scheduled pre-operative appointment. Specific pre-op appointments are only conducted when patients have not been seen by a provider within 4-weeks of their surgical date. If surgery is scheduled within 4-weeks of the patients last encounter with a provider an additional pre-op visit is not required. Since two of the three pre-determined diagnosis of interest are typically associated with trauma, participants may receive their OT consult at their first encounter with the orthopedic surgeon which is also considered their pre-op visit.

The OT consult provided to the individuals assigned to the experimental group will consist of a one-on-one interaction with a third year occupational therapy doctorate (OTD) student providing diagnosis specific educational materials inclusive of what to expect after surgery, the importance of attending therapy as recommended by the orthopedic surgeon and how to accurately complete the Upper Extremity Functional Index (UEFI). Outcomes of this research will include UEFI scores at therapeutic evaluation, after 10 visits and upon discharge, completion of a post operative survey via question pro utilizing a Visual Analog Scale (VAS) at the initial therapeutic encounter, and patient compliance with attending therapy as documented by therapy visit attendance. A semi-structured interview will be completed at patient discharge from therapy to determine areas of possible improvement and further research.

Individuals randomly assigned to the control group will participate in the typical pre-operative experience provided by the orthopedic surgeon. Control group participants will not be made aware of experimental group participants experiences. Participants in the control group will be informed that researchers are interested in the pre-operative patient experiences at Cape Fear Orthopedics \& Sports Medicine and their participation in the study and honest responses.